SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Diamondcutter who wrote (6469)5/5/1999 6:13:00 PM
From: Claud B  Read Replies (1) | Respond to of 7041
 
I agree. Most here would pooh pooh his comments or just refer to
him as "another paid shill" for the company. That's why I didn't
elaborate.

To the other post who referred to "Vasomax not being a secret,"
no one ever said it was.

This latest presentation by SGP gave all the facts in proper
order and the analyst came to certain conclusions.

But then why are we to believe facts! <g>

BTW, I am not referring to a presentation made last year or the year
before. This presentation was made by SGP this past week.



To: Diamondcutter who wrote (6469)5/7/1999 12:51:00 AM
From: Bruce Rosen  Read Replies (2) | Respond to of 7041
 
<< I'd post details, but 80% of the board would not believe it. FWIW, the analyst concluded the drug peak potential to be near $500m annually (sales) at under $7 per pill.>>

Don't be so sure Diamondcutter. Although the shorts have been more vocal here, who knows who is lurking on this thread. I for one would be most appreciative if you did post details.

Good luck,

Bruce


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News